NeoTract Announces Results from Two Studies Demonstrating Transformative Benefits of the UroLift® System for BPH Care
NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced the presentation of new clinical data at the World Congress of Endourology 2018 Annual Conference from two U.K. studies of the company’s novel UroLift® System for patients with Benign Prostatic Hyperplasia (BPH).
“This analysis of the UroLift System demonstrates its transformative impact on BPH care within a major health system,” said Dave Amerson, president of the NeoTract Interventional Urology business unit. “These real-world results continue to support the safety and efficacy of the UroLift System findings of our pivotal trial, and also suggest that the adoption of the UroLift System can save health systems millions in reduced organizational costs when compared to the traditional invasive surgical TURP procedure for patients with BPH.”
U.K. Data Suggests UroLift System Greatly Reduces Costs Associated
The Transforming BPH Surgical Care study compares patient outcomes, resources consumed, and associated costs of treatment for BPH in men treated with the UroLift System compared to those who received TURP using Patient Level Information Costing System (PLICS) at the Leeds Teaching Hospitals NHS Trust in Leeds, England.
Data from this real-world study, presented by Oliver Kayes, M.D., urologist of Leeds Teaching Hospitals NHS Trust, shows that treatment of BPH with the UroLift System shortens operation time while also reducing patients’ hospital stay to an average of 0.4 days, compared to 4.6 days for acute TURP and 1.8 days for elective TURP. Results from this study demonstrate that BPH treatment with the UroLift System reduced overall costs by 42% when compared to the TURP surgery. Further analysis from the single-center study calculates that adoption of the UroLift System for 50% of all BPH surgeries at the hospital would generate an additional annual savings of £42,000, while also saving 300 bed days and 106 hours of operating theatre time each year.
“The results of this study demonstrate that the UroLift System moves BPH procedures into day-case settings, achieving positive patient outcomes without financial investment or increased complications in patients with BPH,” said Dr. Kayes. “Data from this study also suggests that adoption of the UroLift System would increase overall capacity, allowing for healthcare centers to focus on critical cancer targets and waiting times, while reducing delays in both urgent and non-urgent surgery.”
The Cost Reductions study, also presented by Dr. Kayes, compares outcomes and cost following treatment with the UroLift System or TURP. The study analyzed reports on the UroLift System from 2010 onwards, as well as data from the National Health Service Hospital Episode Statistics (HES) database and The Health Improvement Network (THIN) to identify hospitalization and treatment rates for TURP from 2010 to 2016 in England.
The results indicate that the average procedure costs are similar with the UroLift System or TURP, but no hospital stay or follow-up visits are required with the UroLift System. The analysis also accounted for the lower rate of complications with the UroLift System based on published data, which includes minimal need for hospital treatment and no instances of new, sustained erectile or ejaculatory dysfunction. With a conservative estimate of 50% reduction in complications using the UroLift System and 50% adoption in patients who would otherwise undergo a TURP procedure, this analysis indicates that approximately £27 million could be saved by reductions in complications alone. The results from this study are consistent with the Surgical Care study, demonstrating that an increased use of the UroLift System to treat patients with BPH could significantly reduce costs and maintain positive patient outcomes.
About the UroLift System
The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Nearly 70,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The UroLift System Prostatic Urethral Lift procedure is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at www.UroLift.com.
About NeoTract | Teleflex Interventional Urology
A wholly owned subsidiary of Teleflex Incorporated, the NeoTract Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function. Learn more at www.NeoTract.com.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit www.teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose.
Oliver Kayes is a paid consultant to NeoTract | Teleflex Interventional Urology.
MAC00843-03 Rev A
For Teleflex Incorporated
Treasurer and Vice President, Investor Relations
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
C.H. Robinson Acquires Dema Service S.p.A. to Expand Global Presence23.5.2019 14:00:00 EEST | Tiedote
C.H. Robinson (NASDAQ: CHRW) continues to expand its global footprint with its announcement of the acquisition of Dema Service S.p.A. (Dema Service) on May 22, 2019. Dema Service is a leading provider of European road transportation based in Italy. “The acquisition of Dema Service is an exciting milestone for C.H. Robinson and will strengthen our existing footprint in Italy, one of the largest road transportation markets in Europe,” said Jeroen Eijsink, President of Europe for C.H. Robinson. “We are eager to work with Dema Service’s customers to offer our full suite of logistics services to help improve their supply chains.” This is the second European acquisition for C.H. Robinson in 2019. The company recently acquired the freight forwarding group Space Cargo, which expanded C.H. Robinson’s presence in Spain and Columbia. Dema Service is a privately-owned logistics company providing road transportation services across Europe. Headquartered in Pescara, Italy, Dema Service has approxima
Rapid Multiplexing with Opal® Research Kits Now Available on LabSat™ Platform23.5.2019 13:30:00 EEST | Tiedote
Lunaphore Technologies S.A., a Swiss medtech firm developing innovative next-generation equipment for cancer research and tissue diagnostics, announces a new rapid multiplexing application for its LabSat™ Research instrument. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190523005082/en/ FFPE IF of tonsil, 6-plex + DAPI. Total staining time: 4h12 (with Opal® 7-Color Manual IHC Kit) (Photo: Business Wire) Following the signature of a co-marketing agreement between Lunaphore Technologies S.A. and Akoya Biosciences, Inc.; Lunaphore will start providing multiplexing protocols using Akoya’s Opal® immunoassay kits for its staining platform LabSat™ Research, Lunaphore’s first solution to reach the market. LabSat™ is shown to perform rapid tests on tissue samples under 2.5 hours for a 3-plex plus counterstaining with the Opal® 4-Color Manual IHC Kit; and under 4.5 hours for a 6-plex plus counterstaining with the Opal® 7-Color Manua
Network of 1,500 Stroke-Ready Clinics across Europe23.5.2019 13:00:00 EEST | Tiedote
The Angels Initiative announced today at the European Stroke Organisation Conference (ESOC) 2019 in Milan that their three-year goal to create a network of 1,500 stroke-ready centres and hospitals across Europe has been achieved. The Angels Initiative is a unique healthcare approach to improve care for people who have just suffered a stroke (acute stroke care) across Europe and in emerging markets. It is run by Boehringer Ingelheim in partnership with the European Stroke Organisation (ESO), the World Stroke Organisation (WSO), the Stroke Alliance for Europe (SAFE) and many other national stroke societies and companies. “Stroke is one of the leading causes of disability and death. And when a stroke strikes, every second counts to deliver optimised care as fast as possible to preserve life and minimise disability,” commented Prof. Valeria Caso, past president of the ESO. “There is a need to vastly improve the quality and speed of stroke care in Europe. I’m delighted that through the Ange
Dawex Raises €5 Million to Accelerate the Development of the Data Economy23.5.2019 09:45:00 EEST | Tiedote
Dawex, a leading data exchange technology company and the operator of the largest data marketplace, today announced a new round of funding of €5 million with Amadeus (AMS.MC), Itochu Corporation (ITOCY), Bouygues Construction (BOUY.PA) and a French web entrepreneur entering Dawex’s capital, also joined by the historical investor Caisse des Dépôts (via its Banque des Territoires). Total funds raised from inception tops €12 million, including the recent €2.5M grant from Horizon 2020, the biggest European Union Research & Innovation program. Dawex co-founders Fabrice Tocco and Laurent Lafaye remain majority shareholders, retaining full control over the company’s strategy and operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190522005927/en/ With the rise of Artificial Intelligence, Internet of Things, and the emergence of Smart Cities, among other disruptive trends like the autonomous cars, huge quantities of valuable
TTS Pharma Limited Announces Closing of £10.3 Million Fundraising and New Board Appointment23.5.2019 09:00:00 EEST | Tiedote
COMPLETION OF SERIES B FUNDRAISE TTS Pharma Limited (“TTS Pharma” or the “Company”), a UK company which is a vertically integrated supply chain manager in the cultivation, manufacturing and development of the emerging ethical cannabis market, announces that it has successfully closed a private equity investment totalling £10.3 million, on the basis of a two-tranche investment. This investment will permit TTS Pharma to become one of the leading global suppliers in this fast-growing multibillion-dollar industry, by allowing it to expand its existing supply chain, develop its own facilities and further strengthen its academic and commercial partnerships. It also enables the Company to advance its diversified operations in the wellness, nutraceutical and pharmaceutical sectors. The ethical cannabis market is set to become a high growth, disruptive and innovative new segment in the life sciences field and TTS Pharma is ideally positioned to capture rapid value within this market. BOARD UPDA
Buy and Sell Globally: 2019 Yiwu Imported Commodities Fair Opens in “World’s Capital of Small Commodities”23.5.2019 07:46:00 EEST | Tiedote
On May 23-26, China Yiwu Imported Commodities Fair 2019 opened at Yiwu International Expo Center in Eastern China’s Yiwu city – the world’s capital of small commodities. The Fair of this year provides 2,012 standard booths in five halls, namely Asia I, Asia II, Europe, America-Australia-Africa & Cross-border Trade & Zhenjiang-International Sister Cities Exchange, and Imported Sweets and Wines, with an exhibition area of over 50,000m2 . Among the nearly 1,000 exhibitors from 85 countries and regions, 170 are from 40 countries and regions along the “Belt and Road” to exhibit daily necessities, home supplies, handicrafts, foods and drinks. Echoing China International Import Expo (CIIE), a special area is reserved for over 20 CIIE companies to exhibit their quality products including Bosch Group (Germany), skin care brand Rilastil (Italy), and Alligga (Canada) specializing in health products for a complete and balanced lifestyle. In addition, a special area for international sister cities
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme